Today the Federal Circuit affirmed a bench trial judgment that the obviousness doctrine didn’t invalidate patent claims relating to antidiabetic agents. Although the judgment predated KSR Int’l Co. v. Teleflex Inc., 127 S. Ct. 1727 (2007), the court held that it it applied correct principles in analyzing the obviousness question. Takeda Chemical Industries, Ltd. v. Alphapharm Pty., Ltd., No. 06-1329 (Fed. Cir. June 28, 2007).